Статья

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

Xiangyu ChenInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaZhiwei PanInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaShuai YueInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaFei YuInstitute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, 510080, Guangzhou, ChinaJunsong ZhangGuangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, ChinaYang YangInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaLi RenCollege of Veterinary Medicine, Northeast Agricultural University, 150030, Harbin, Heilongjiang, ChinaBingfeng LiuInstitute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, 510080, Guangzhou, ChinaXiaofan YangInstitute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, 510080, Guangzhou, ChinaLeiqiong GaoInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaZhirong LiInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaYao LinInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaQizhao HuangCancer Center, The General Hospital of Western Theater Command, 610083, Chengdu, Sichuan, ChinaLifan XuInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaJianfang TangInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaHu LiInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, ChinaJing ZhaoBiomedical Analysis Center, Third Military Medical University, 400038, Chongqing, ChinaPinghuang LiuComparative Immunology Research Center, College of Veterinary Medicine, China Agricultural University, 100193, Beijing, ChinaGuozhong ZhangKey Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, 100193, Beijing, China. [email protected]Yaokai ChenChongqing Public Health Medical Center, 400038, Chongqing, China. [email protected]Kai DengGuangzhou Eighth People's Hospital, Guangzhou Medical University, 510050, Guangzhou, China. [email protected]Lilin YeInstitute of Immunology, PLA, Third Military Medical University, 400038, Chongqing, China. [email protected]

2020en

ABI

Аннотация

COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild, and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.

Перевод пока недоступен

Идентификаторы

DOI: 10.1038/s41392-020-00301-9

Цитирования и источники

Цитирований: 3Использованных источников: 0

Показатели — AkademScholar